What is 3Daughters?
3Daughters operates as a specialized clinical development entity dedicated to evolutionary healthcare solutions for women. The company occupies a unique niche in the medical technology sector, focusing on neglected health issues that have historically lacked sufficient research and innovation. By targeting the IUD market, 3Daughters aims to dismantle long-standing barriers to adoption, specifically addressing the issue of insertion pain. This focus on patient-centric design and clinical efficacy positions the firm as a disruptive force in reproductive health, bridging the gap between academic research and commercialized medical solutions.
The company's operational model leverages deep scientific expertise to transform standard procedures into more accessible, less invasive experiences. By prioritizing the development of next-generation medical devices, 3Daughters is not merely iterating on existing technology but is fundamentally rethinking the standard of care for women globally.
How much funding has 3Daughters raised?
3Daughters has raised a total of $6.7M across 1 funding round:
Angel/Seed
$6.7M
Angel/Seed (2024): $6.7M with participation from University of Massachusetts - Amherst, Argosy Foundation, Thairm Bio, and Wexford Science & Technology
Key Investors in 3Daughters
University of Massachusetts - Amherst
A public research and land-grant university that supports academic innovation and the translation of research into practical healthcare solutions.
Argosy Foundation
A private family foundation focused on supporting entrepreneurial solutions and systemic challenges across health, education, and the arts.
Wexford Science & Technology
A developer of mixed-use spaces that fosters innovation by collaborating with research institutions and healthcare systems to accelerate discovery.
What's next for 3Daughters?
With the recent infusion of capital, 3Daughters is poised to transition from early-stage research into more advanced clinical development phases. The strategic roadmap likely involves scaling its R&D capabilities and navigating the complex regulatory landscape required for medical device approval. By utilizing the $6.7M investment, the company will likely focus on clinical trials and the refinement of its proprietary technology to ensure it meets the highest safety and efficacy standards. As the firm matures, its ability to demonstrate tangible improvements in patient outcomes will be the primary driver for future growth and potential market entry. The backing from diverse institutional and philanthropic partners suggests a robust support network that will facilitate long-term sustainability and impact in the women's health sector.
See full 3Daughters company page
